{"id":165226,"date":"2025-01-20T15:44:51","date_gmt":"2025-01-20T14:44:51","guid":{"rendered":"https:\/\/stratec-med.com\/literatur\/physical-activity-in-youth-with-osteogenesis-imperfecta-type-i-2\/"},"modified":"2025-01-20T15:44:52","modified_gmt":"2025-01-20T14:44:52","slug":"physical-activity-in-youth-with-osteogenesis-imperfecta-type-i-2","status":"publish","type":"literatur","link":"https:\/\/stratec-med.com\/en\/literature\/physical-activity-in-youth-with-osteogenesis-imperfecta-type-i-2\/","title":{"rendered":"Physical activity in youth with osteogenesis imperfecta type I."},"content":{"rendered":"<p>INTRODUCTION: Individuals with Osteogenesis Imperfecta (OI) type I often show muscular weakness. However, it is unclear whether muscular weakness is a consequence of physical inactivity or a result of the disease itself. The aim was to assess muscle function in youth with OI type I and evaluate physical activity  (PA). METHODS: Fourteen children with OI type I (mean age [SD]: 12.75 [4.62] years) were compared to 14 age- and gender-matched controls (mean age [SD]: 12.75 [4.59] years). Muscle force and power were determined through mechanography. PA and daily energy expenditure were measured with an accelerometer and a questionnaire. RESULTS: Compared to controls, children with OI type I had lower muscle force and power. OI type I children were as active as their healthy counterparts. CONCLUSIONS: Children and adolescents with OI type I and their healthy counterparts did not reached daily recommendations of PA. Given their muscle function deficit, youth with OI type I would benefit to reach these recommendations to prevent precocious effect of aging on muscles.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>INTRODUCTION: Individuals with Osteogenesis Imperfecta (OI) type I often show muscular weakness. However, it is unclear whether muscular weakness is<\/p>\n","protected":false},"author":22,"parent":0,"menu_order":0,"template":"","format":"standard","meta":{"_acf_changed":false},"tags":[],"thema":[5870,5922,5924,5866,5878,5856],"produktgruppe":[5827],"literatur_kategorie":[7221],"class_list":["post-165226","literatur","type-literatur","status-publish","format-standard","hentry","thema-basics","thema-clinical-application","thema-clinical-studies","thema-diagnostics-using-leonardo-pqct","thema-medical-applications","thema-therapy-prevention-using-galileo","produktgruppe-leonardo-en","literatur_kategorie-clinical-studies"],"acf":[],"_links":{"self":[{"href":"https:\/\/stratec-med.com\/en\/wp-json\/wp\/v2\/literatur\/165226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stratec-med.com\/en\/wp-json\/wp\/v2\/literatur"}],"about":[{"href":"https:\/\/stratec-med.com\/en\/wp-json\/wp\/v2\/types\/literatur"}],"author":[{"embeddable":true,"href":"https:\/\/stratec-med.com\/en\/wp-json\/wp\/v2\/users\/22"}],"version-history":[{"count":0,"href":"https:\/\/stratec-med.com\/en\/wp-json\/wp\/v2\/literatur\/165226\/revisions"}],"wp:attachment":[{"href":"https:\/\/stratec-med.com\/en\/wp-json\/wp\/v2\/media?parent=165226"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stratec-med.com\/en\/wp-json\/wp\/v2\/tags?post=165226"},{"taxonomy":"thema","embeddable":true,"href":"https:\/\/stratec-med.com\/en\/wp-json\/wp\/v2\/thema?post=165226"},{"taxonomy":"produktgruppe","embeddable":true,"href":"https:\/\/stratec-med.com\/en\/wp-json\/wp\/v2\/produktgruppe?post=165226"},{"taxonomy":"literatur_kategorie","embeddable":true,"href":"https:\/\/stratec-med.com\/en\/wp-json\/wp\/v2\/literatur_kategorie?post=165226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}